Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	846.80B
Revenue (ttm)	1.12T
Net Income (ttm)	-14.26B
Shares Out	76.43M
EPS (ttm)	-255.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216,609
Average Volume	179,120
Open	10,920
Previous Close	10,850
Day's Range	10,920 - 11,340
52-Week Range	9,260 - 18,500
Beta	0.44
RSI	47.87
Earnings Date	Aug 13, 2025

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 278
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.